New Jersey Is Pulling 150,000 Gallons of Cancer-Causing Foam From Its Firehouses — If You Used It, You Need to Read This
You spent years pulling on turnout gear and hauling lines of aqueous film-forming foam into training burns, fuel-fire calls, and hazmat scenes. Nobody told you the foam was loaded with chemicals that never leave the body. Nobody told you it was designed with fluorosurfactants — the same “forever chemicals” that the federal government has now classified as hazardous substances. Nobody told you that the state of New Jersey would eventually call what you were spraying “cancer-causing” and spend $16.6 million to collect and destroy it. Now you have a diagnosis, or someone you served with has one, and you are reading this at a kitchen table at 2 a.m. trying to understand whether the foam and the cancer are connected — and whether anyone can be held accountable for what was done to you.
We are Attorney911. We are a trial firm that handles toxic exposure and mass tort cases for people who were given a dangerous product and told it was safety equipment. Ralph Manginello has spent 27-plus years in courtrooms, including federal court, and before he was a lawyer he was a journalist — he learned to find the documents people do not want found. Lupe Peña spent years inside a national insurance-defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue claims from people exactly like you — and now he sits on your side of the table. We are writing this page to tell you the truth about what New Jersey just did, what it means for your legal rights, and what you need to do before the evidence and the deadline both disappear.
What Just Happened in New Jersey — and Why It Matters to You
In March 2026, two New Jersey state agencies — the Department of Environmental Protection and the Department of Community Affairs — announced what they called one of the largest cooperative collection programs of its kind in the nation. The state identified more than 400 fire departments eligible to participate. The state expects to collect approximately 150,000 gallons of PFAS-containing firefighting foam. A contractor will transport it to an Ohio facility where the chemicals will be permanently destroyed through a process called supercritical water oxidation — breaking the carbon-fluorine bonds that make these molecules nearly indestructible.
The state funded this with a $16.6 million appropriation. The legislation behind it — P.L. 2023, c.243 — was signed into law in 2024 and originally set a January 8, 2026 deadline for fire departments to stop using PFAS-containing foam. That deadline was extended to January 1, 2027. The law directs the DEP to run the collection program and bans the use and storage of these foams after that date.
Here is what the state’s own officials said when they announced this program. The acting commissioner of the DEP called the foams “dangerous chemicals” and said the state was “keeping them out of the environment and avoiding the extremely high cost of cleanup down the road.” The commissioner of the Department of Community Affairs called them “cancer-causing firefighting foam.” The state fire marshal said it was time to “transition from these PFAS containing foams and move to safer fluorine-free alternatives.”
And the president of the New Jersey State Firefighters Mutual Benevolent Association — the organization representing the firefighters themselves — said something that should stop every firefighter in the country in their tracks:
“Cancer in the fire service is our number one killer. The NJFMBA is grateful for the partnership with our Legislature and Governor Sherrill for taking action to reduce long-term health concerns and ensure safer conditions for New Jersey’s first responders. We are the front lines of defense for our state and deserve nothing less than common sense collaboration to ensure New Jersey provides the protection, staffing and equipment for our women and men to do their jobs safely.”
That statement is not from a plaintiff’s lawyer. It is from the union representing New Jersey firefighters, in an official government press release, announcing that the product firefighters were required to use is killing them.
That announcement is the moment the government stopped being silent. And it matters for your case — because when a state formally calls a product “cancer-causing” and spends $16.6 million to remove it, the argument that nobody could have known the foam was dangerous becomes a great deal harder for the manufacturers to make.
Can My Cancer Be Connected to Firefighting Foam?
Yes — it can be, and the connection is supported by both government science and ongoing litigation. But the honest answer is that proving the connection in your individual case requires medical evidence, exposure history, and expert analysis. The general causation link — that PFAS causes certain cancers — is well-established and government-acknowledged. The specific causation link — that your cancer was caused by your exposure to AFFF — is what a case is built to prove.
Here is what we know. PFAS — per- and polyfluoroalkyl substances — are synthetic chemicals that do not break down in the human body or the environment. They bioaccumulate. That means every exposure adds to the burden already in your blood, your liver, your kidneys. The half-life of some PFAS compounds in the human body is measured in years, not days. You can read more about how these toxic exposure cases work on our toxic tort claim page.
The International Agency for Research on Cancer — the world’s leading cancer science authority — classified PFOA as a Group 1 carcinogen, meaning it is carcinogenic to humans. PFOS was classified as Group 2B, possibly carcinogenic to humans. The C8 Science Panel, an independent group of epidemiologists who studied a population of approximately 69,000 people exposed to PFOA through contaminated drinking water, found a “probable link” between PFOA and six health conditions: kidney cancer, testicular cancer, high cholesterol, thyroid disease, pregnancy-induced hypertension, and ulcerative colitis. Those findings have been the foundation of PFAS litigation for over a decade.
The federal government has also acted. In April 2024, the EPA finalized the first-ever national drinking water regulation for PFAS, setting the maximum contaminant level for PFOA and PFOS at 4.0 parts per trillion — a number so small it is essentially a declaration that there is no safe amount. The EPA set the health-based maximum contaminant level goal at zero. In May 2024, the EPA designated PFOA and PFOS as hazardous substances under CERCLA — the Superfund law — making the companies that released them responsible for cleanup costs and triggering federal reporting requirements for releases of one pound or more in a 24-hour period.
These are not ambiguous signals. The government has concluded that these chemicals are dangerous, that they cause cancer, and that the companies that made and distributed them bear responsibility for the contamination.
Which Cancers and Diseases Are Linked to PFAS Exposure
The diseases most strongly associated with PFAS exposure through AFFF and contaminated drinking water include:
- Kidney cancer — one of the two cancers with the strongest C8 Science Panel “probable link” finding
- Testicular cancer — the other cancer with the strongest probable-link finding
- Thyroid cancer and thyroid disease — documented in the C8 Science Panel findings
- Prostate cancer — studied in relation to PFAS exposure in firefighter populations
- Ulcerative colitis — a chronic inflammatory bowel disease linked to PFOA exposure
- Immune system dysfunction — PFAS is known to suppress immune response, potentially reducing vaccine effectiveness and increasing infection susceptibility
- Liver damage — PFAS accumulates in the liver and is associated with elevated liver enzymes and fatty liver disease
- High cholesterol — the C8 Science Panel found a probable link between PFOA and elevated cholesterol
- Pregnancy-induced hypertension — including preeclampsia, linked to PFOA exposure
The cancers that drive the most AFFF personal-injury litigation are kidney cancer and testicular cancer, because the scientific evidence linking those to PFAS is the strongest. But thyroid cancer, prostate cancer, and other malignancies are also being pursued, and the science connecting PFAS to those diseases continues to develop.
If you are a firefighter — active or retired — and you have been diagnosed with any of these conditions, and you used AFFF in training or emergency response over a period of years, the connection between your exposure and your diagnosis is something that can and should be investigated. That investigation starts with documenting your exposure history and getting serum PFAS blood testing to establish your current body burden.
Who Is at Risk: Firefighters, Training Exercises, and Contaminated Gear
The risk is not limited to one kind of firefighter. Anyone who handled, sprayed, stored, or was in the vicinity of AFFF during discharge is at risk. That includes:
Municipal firefighters who used AFFF at training exercises — where the foam was sprayed deliberately, often in large quantities, for practice. Training burns were among the most intensive exposure events. Firefighters stood in the foam, walked through it, got it on their skin and in their airway, and then cleaned it up or hosed it away — often without protective equipment beyond their standard turnout gear.
Airport firefighters — military and civilian — because AFFF was the standard extinguishing agent for fuel fires at airports for decades. The FAA required AFFF at commercial airports, and the military used it extensively. Studies have found elevated PFAS levels in water sources near military bases and airports where AFFF was used extensively.
Industrial firefighters at refineries, chemical plants, and manufacturing facilities where flammable liquid fires were a foreseeable hazard and AFFF was the designated response.
Hazmat technicians who handled AFFF concentrates, performed equipment testing, or managed foam-system discharge.
Firefighters exposed through contaminated turnout gear — and this is a separate exposure pathway that the NJFMBA president specifically identified. PFAS has been used in the manufacture of turnout gear, and firefighters absorb it through dermal contact with their own protective equipment. Every time you sweated in that gear, every time you pulled it on and off, you may have been absorbing chemicals through your skin. Gear manufacturers face their own potential liability for this separate exposure route.
The exposure pathways are dermal (absorption through the skin), inhalation (breathing in aerosolized foam during discharge), and ingestion (contaminated drinking water at the station, hand-to-mouth transfer after handling foam without adequate decontamination). A firefighter who used AFFF regularly over a career of 10, 20, or 30 years accumulated a substantial body burden — one that can be measured today through a blood test.
Why the Government Calling This Foam “Cancer-Causing” Matters for Your Case
When a state government formally calls a product “cancer-causing” — in an official press release, through a cabinet-level commissioner, backed by a $16.6 million appropriation to remove it — that statement is powerful evidence in a product liability case. It does not prove that the manufacturer is legally liable for your specific cancer. But it does several things that matter:
It destroys the “no one knew” defense. Manufacturers of AFFF have argued, and will continue to argue, that the science was evolving and that they could not have known their products were dangerous. When a state government concludes the product is cancer-causing and passes legislation to ban it, the argument that the danger was unknowable becomes difficult to maintain.
It establishes the standard of care. The fact that the state of New Jersey — which has been at the forefront of PFAS regulation nationally — concluded that these foams must be removed from service tells a jury that the danger was recognized, documented, and serious enough to warrant a multi-million-dollar government response.
It supports the failure-to-warn theory. If the product was dangerous enough that the state is spending $16.6 million to collect and destroy it, the question becomes: why were firefighters not warned? Why were they told this was safety equipment? Why did the manufacturers continue to sell a product whose core functional component — fluorosurfactants — is a bioaccumulative carcinogen?
It provides context for punitive damages. New Jersey permits punitive damages in product liability cases where a defendant acted with wanton and reckless disregard for the safety of others. If discovery reveals that AFFF manufacturers possessed internal toxicity data showing PFAS cancer risks and suppressed or minimized that information while continuing to market AFFF to fire departments, the government’s own characterization of the foam as “cancer-causing” becomes part of the foreseeability and conscious-disregard narrative that drives punitive claims.
The Manufacturers: Who Made This Foam and What They Knew
The defendants in AFFF/PFAS litigation are not individual firefighters or fire departments. They are the major chemical companies that designed, produced, formulated, and distributed PFAS-containing firefighting foam over a period of decades. These are some of the largest corporations in the chemical industry.
The companies include the primary fluorochemical manufacturers that produced the PFAS raw materials, the formulators that blended those materials into finished AFFF products, and the marketers that sold those products to fire departments, airports, military installations, and industrial facilities across the country.
Some of these companies have already entered into massive settlement agreements — but those settlements are for public water providers, not for individual firefighters with cancer. The 3M Company agreed to a settlement valued at approximately $10.3 billion in present value (up to roughly $12.5 billion over 13 years) to public water systems for PFAS remediation. DuPont, Chemours, and Corteva agreed to approximately $1.185 billion with public water providers. These are real numbers, and they prove that the companies have accepted financial responsibility for the contamination — but that money is for cleaning water systems, not for compensating a firefighter who developed kidney cancer after years of spraying AFFF.
The corporate structure of these defendants is designed to make recovery difficult. Chemours was spun off from DuPont in 2015 and holds much of the legacy PFAS liability. DuPont itself was broken apart in the DowDuPont merger and reorganization. 3M announced it would exit PFAS manufacturing entirely by the end of 2025. These restructuring moves — spinoffs, mergers, exits — are not accidents. They are designed to put corporate walls between the injured person and the company that made the product. Naming the right entity, the entity that actually designed and sold the foam, is one of the first and most important things a lawyer does in these cases.
And then there is the question of what they knew. The federal AFFF litigation — consolidated as Multidistrict Litigation No. 2873 in the U.S. District Court for the District of South Carolina before Judge Richard M. Gergel — has been working through discovery on exactly that question. As of mid-2026, the MDL had more than 15,000 actions pending. The discovery targets include internal corporate communications, scientific studies, regulatory submissions, and safety testing records — documents that may show whether manufacturers knew about PFAS toxicity and cancer risk decades before the government acted. If those documents show what plaintiffs’ lawyers believe they show — internal knowledge of bioaccumulation, toxicity, and cancer risk that was suppressed or minimized — they drive both liability and punitive damages.
Your Legal Rights: Product Liability Claims Against AFFF Manufacturers
AFFF/PFAS cancer cases are built on product liability law. The core theory is that the manufacturers designed, sold, and distributed a product that was unreasonably dangerous — and that they failed to warn the people who used it of the cancer and health risks.
There are several legal theories that these cases pursue:
Strict product liability — design defect. The argument is that PFAS-containing AFFF was unreasonably dangerous by design. The product’s core functional component — fluorosurfactants — is a bioaccumulative carcinogen that persists indefinitely in the human body and environment. Safer fluorine-free alternatives existed and were available for most municipal firefighting applications, rendering the product design defective. When a product’s essential ingredient is a “forever chemical” that accumulates in the body and causes cancer, and safer alternatives were available, the design itself is the defect.
Strict product liability — failure to warn. The manufacturers failed to adequately warn firefighters, fire departments, and regulatory bodies of the cancer, immune-system, and organ-damage risks associated with repeated PFAS exposure through dermal contact, inhalation, and ingestion during foam application, training, and equipment cleanup. The question is not whether the foam worked at putting out fires — it did. The question is whether the people spraying it were told what it would do to their bodies. If the answer is no — and for decades, the answer was no — that is a failure to warn.
Negligent design and marketing. Manufacturers knew or should have known of PFAS bioaccumulation and toxicity from decades of internal and published scientific literature. The fluorosurfactant chemistry that makes AFFF effective at suppressing Class B fires is the same chemistry that makes it bioaccumulative and carcinogenic. That is not a secret that was discovered yesterday — the scientific literature on PFAS toxicity has been accumulating for decades. A manufacturer that continued to design, market, and distribute AFFF for widespread municipal and industrial use without adequate safety warnings or a transition to safer alternatives may have been negligent.
Fraudulent concealment. If discovery reveals that manufacturers possessed internal toxicity data showing PFAS cancer risks and suppressed or minimized that information while continuing to market AFFF to fire departments, plaintiffs may pursue claims for concealment of material safety information. This theory is important not just for damages but for the statute of limitations — if a manufacturer actively concealed the danger, the discovery rule may toll the limitations period, meaning the clock on your deadline to file may not have started running until you learned the foam caused your cancer.
Toxic tort — medical monitoring. Firefighters with documented prolonged AFFF exposure who have not yet developed cancer may pursue medical monitoring claims. These claims seek the cost of periodic serum PFAS testing, cancer screening, and diagnostic surveillance — because the established latency period and elevated cancer risk in the firefighter population make ongoing monitoring a medical necessity, not a luxury. You can read more about workplace and occupational disease claims on our workplace injury page.
Wrongful death. If a firefighter succumbed to a PFAS-associated cancer, the family may bring a wrongful death claim. If the connection between the AFFF exposure and the cancer was not understood during the decedent’s lifetime — which for many firefighters it was not — the discovery rule may mean the wrongful death clock started running later than the date of death. We discuss wrongful death claims in more detail on our wrongful death claim page.
New Jersey’s Legal Framework: What Makes This State Different
New Jersey has been at the forefront of PFAS regulation and is among the most aggressive states in addressing PFAS contamination through both legislation and litigation. P.L. 2023, c.243 — the law that authorized the collection program and banned PFAS-containing firefighting foam use and storage after January 1, 2027 — is the controlling New Jersey statute. New Jersey also maintains some of the nation’s strictest state-level PFAS drinking water maximum contaminant levels, having set those standards years before federal EPA action.
For your legal case, several features of New Jersey law matter:
The statute of limitations. New Jersey’s statute of limitations for personal injury claims is two years. New Jersey’s wrongful death statute also provides a two-year limitations period. But for toxic tort cases like AFFF/PFAS exposure, New Jersey follows the discovery rule — meaning the clock may not start running on the date you were exposed to the foam. It may start running on the date you discovered, or by reasonable diligence should have discovered, both your injury (the cancer diagnosis) and its potential cause (the AFFF/PFAS exposure). For a firefighter diagnosed with kidney cancer in 2024 who only learned in 2026 that AFFF contained cancer-causing PFAS, the clock may have started running far more recently than the date of diagnosis. This is one of the most important issues in your case, and it is why you should not assume you are out of time without consulting a lawyer who understands toxic tort accrual.
Comparative fault. New Jersey applies a modified comparative negligence rule — the 50% bar rule. Your own share of fault reduces your recovery, and if you are found to be 50% or more at fault, you are barred from recovery. In the AFFF context, the defense may try to argue that firefighters knew or should have known the foam was dangerous, or that other exposures (smoking, other occupational carcinogens) contributed to the cancer. The answer is that firefighters were required to use AFFF as part of their job — they were not given a choice — and the manufacturer’s duty to warn runs to the end user who was never told. A firefighter who followed department protocol and used the equipment provided is not at fault for trusting that the equipment was safe.
Punitive damages. New Jersey permits punitive damages in product liability cases where a defendant acted with wanton and reckless disregard for the safety of others, subject to statutory limitations under New Jersey’s Punitive Damages Act. If discovery reveals that AFFF manufacturers possessed internal data showing PFAS cancer risks and continued to market the product without adequate warnings, punitive damages become a real possibility — and the threat of punitive damages is one of the most powerful settlement levers in mass tort litigation.
The Rubanick evidentiary standard. New Jersey courts generally apply the Rubanick product liability evidentiary standard, which can be more plaintiff-favorable than the federal Daubert standard for toxic tort expert testimony. Under this standard, novel scientific evidence may be admissible in New Jersey courts under conditions that are more accessible to plaintiffs than the federal rule — which matters when your case depends on expert testimony linking PFAS exposure to your specific cancer.
The National AFFF Litigation: MDL Status and What It Means for Your Case
The federal AFFF mass tort litigation has been consolidated in multidistrict litigation — MDL No. 2873, titled In re: Aqueous Film-Forming Foams Products Liability Litigation — before Judge Richard M. Gergel in the U.S. District Court for the District of South Carolina. As of mid-2026, the MDL had more than 15,000 actions pending, encompassing both water-provider contamination claims and personal-injury claims by firefighters and others exposed to AFFF.
An MDL is not a class action. Each plaintiff keeps an individual case. The MDL centralizes pretrial work — discovery, motion practice, bellwether trials — so that one judge can manage the shared issues efficiently rather than having 15,000 separate cases in 15,000 separate courts. The MDL process typically works through bellwether trials — test cases selected to go to trial first, whose results inform settlement negotiations for the remaining cases.
The public water-provider settlements — 3M’s approximately $10.3 billion present-value agreement and the DuPont/Chemours/Corteva approximately $1.185 billion agreement — are separate from the personal-injury claims. A firefighter with cancer is not covered by the water-system money. Those settlements resolve municipal contamination claims and contain no admission of liability. The personal-injury cases — the cases brought by firefighters who developed cancer after years of AFFF exposure — are a separate track within the MDL.
The first AFFF personal-injury bellwether was selected to focus on kidney cancer. It had been scheduled for trial but was postponed after the court identified a large backlog of unfiled cases. The bellwether schedule is moving, and anyone considering a claim should not wait to see how the bellwether trials turn out before acting — because the statute of limitations clock runs regardless of what happens in the MDL, and evidence deteriorates while the MDL process unfolds.
Medical Monitoring: What to Do Even Without a Cancer Diagnosis
If you are a firefighter with documented AFFF exposure and you have not been diagnosed with cancer, you should still consider two things: getting your serum PFAS levels tested, and exploring whether a medical monitoring claim is available to you.
Serum PFAS blood testing provides direct biomarker evidence of PFAS bioaccumulation in your body. It measures the concentration of specific PFAS compounds — including PFOA, PFOS, PFHxS, and others — in your blood serum. These levels reflect your cumulative exposure over your lifetime. The testing is available through specialized laboratories, and the results serve two purposes: they tell you and your doctor what your current body burden is, and they provide foundational evidence for specific causation if you later develop a PFAS-associated disease.
There is a time element here. PFAS serum levels decline slowly over time — but they decline. The longer you wait to test, the lower your detected levels may be compared to your peak exposure. Testing now captures a more accurate picture of your cumulative body burden than testing five years from now. If you are no longer actively exposed to AFFF — because the foam has been removed from your department or you have retired — your levels are already declining. The test you take today is the best test you will ever have.
Medical monitoring claims seek the cost of ongoing surveillance — periodic serum PFAS testing, cancer screening appropriate to your exposure profile (renal imaging for kidney cancer risk, testicular ultrasound for testicular cancer risk, thyroid panels for thyroid disease risk), and diagnostic follow-up. The rationale is straightforward: you were exposed to a known carcinogen through no fault of your own, the cancer may not appear for years or decades, and early detection improves outcomes. The manufacturer that exposed you should bear the cost of watching for the disease it created the risk of.
The Evidence Clock: What Records Exist and How Fast They Disappear
This is the section that determines whether your case can be proven. The evidence that connects your cancer to AFFF exposure exists right now — but it will not exist forever. Some of it is on a clock that is already running.
Fire department AFFF purchase, inventory, and usage records. These establish the volume, type, and duration of PFAS-containing foam to which you were exposed. They are critical for specific causation — proving how much foam you were around, for how long, and which products. But here is the danger: as departments transition to fluorine-free alternatives under the 2027 deadline, legacy purchasing records may be archived, discarded, or lost during administrative transitions. The state’s collection program itself may trigger records purges as departments clear out old materials. These records need to be preserved now.
Fire incident and training reports documenting AFFF deployment. These corroborate individual firefighter exposure events and frequency for dose reconstruction. Historical run reports and training logs may be stored in inconsistent formats across 400+ departments — some paper, some digital, some on systems that are being replaced. The department’s records retention policy varies, and there is no uniform federal mandate that these survive.
Serum PFAS blood testing results. As discussed above, these provide direct biomarker evidence linking your exposure to your internal dose. PFAS serum levels reflect cumulative exposure but decline slowly over time. Testing should be conducted promptly to capture current body burden before continued elimination reduces detected levels.
Manufacturer internal documents. These are the documents that drive punitive damages and fraudulent concealment claims — internal corporate communications, scientific studies, safety testing records, and regulatory submissions that may show knowledge of cancer risk and failure to warn. These documents are primarily in the defendants’ possession and will require targeted discovery in the MDL or individual litigation. Preservation letters should be sent immediately to prevent routine document-destruction policies from eliminating relevant communications.
Firefighter turnout gear and PPE testing for PFAS contamination. The NJFMBA explicitly identified contaminated gear as a separate exposure pathway. Gear testing may support parallel claims against equipment manufacturers. Departments may begin replacing PFAS-treated gear during the transition period — contaminated gear should be preserved and tested before disposal. Once that gear is thrown away, the physical evidence of a second exposure pathway is gone.
Environmental and drinking water testing data from fire station properties and surrounding areas. This documents environmental contamination from AFFF use and storage, supporting property damage and potential bystander exposure claims. The statewide collection program may trigger concurrent environmental assessments. Sampling data should be obtained before site remediation alters baseline conditions.
The preservation letter — a formal written demand that relevant parties preserve all evidence related to your exposure and injury — is one of the first things that goes out when you contact a lawyer. That letter creates a legal obligation. If evidence is destroyed after a preservation letter is on file, the consequences can include adverse-inference instructions (the jury may assume the lost evidence was as bad as the plaintiff says it was), sanctions, and in some cases separate claims for the destruction itself.
What Your Case Is Worth: Damages in AFFF/PFAS Cancer Claims
AFFF/PFAS exposure cases involve catastrophic damages. The cancers associated with PFAS — kidney cancer, testicular cancer, thyroid cancer — can require surgery, chemotherapy, radiation, immunotherapy, and in some cases lifelong treatment. They can end a career, end a life, and destroy a family’s financial security.
Based on the forensic analysis of AFFF mass tort cases, individual firefighter cancer claims typically range from approximately $500,000 on the low end to $5,000,000 or more on the high end. The wide range reflects the variables that determine value:
Cancer type and severity. Kidney cancer and testicular cancer — the two cancers with the strongest scientific link to PFAS — carry higher values because the general causation evidence is strongest. A cancer that has metastasized or required organ removal carries a higher value than one caught early and treated surgically.
Duration and intensity of AFFF exposure. A firefighter who used AFFF in training exercises monthly for 25 years has a stronger exposure profile than one who encountered it occasionally over 5 years. The exposure history is what dose reconstruction is built on, and the dose is what specific causation experts use to tie the cancer to the foam.
Availability of serum PFAS biomarker data. A firefighter who has a blood test showing elevated PFAS levels has direct evidence of bioaccumulation. That is foundational for specific causation and makes the case materially stronger.
Strength of specific causation expert testimony. The expert who testifies that your cancer was caused by your AFFF exposure — typically a board-certified oncologist or epidemiologist — must connect the general science to your individual facts. That connection is built from your exposure history, your serum levels, your medical records, and the published literature on PFAS and your cancer type.
Forum. Where your case is filed matters. New Jersey’s legal framework — including its plaintiff-favorable evidentiary standard and its punitive damages availability — can affect value. The MDL’s bellwether results and settlement framework also influence what individual cases are worth.
Medical monitoring claims for exposed-but-asymptomatic firefighters carry lower individual values but may support collective treatment. The cost of annual serum testing, cancer screening, and diagnostic surveillance over a firefighter’s remaining life expectancy is a calculable economic stream — and it is a cost the manufacturers should bear, not the firefighters.
Wrongful death claims may apply for firefighters who succumbed to PFAS-associated cancers. Survival actions capture the decedent’s pre-death pain and suffering — the months or years of treatment, the fear, the physical decline. The value of a wrongful death case depends on the age of the decedent, their earning capacity, their family structure, and the strength of the causation evidence. Our wrongful death page discusses these claims in more depth.
Past results depend on the facts of each case and do not guarantee future outcomes. The figures above reflect the general range of AFFF mass tort claim values based on the stage of the litigation, the nature of the injuries, and the defendants involved. Your individual case value depends on your specific facts, your specific diagnosis, and your specific exposure history.
The Insurance Playbook: What to Expect from the Other Side
Lupe Peña spent years inside a national insurance-defense firm. He sat in the rooms where adjusters and their software decided how to value, deny, and devalue claims. He knows the plays because he used to run them. Here are the plays the other side will run on an AFFF cancer claim — and here is what we do about each one.
Play 1: “Your cancer came from something else.” The defense will argue that kidney cancer, testicular cancer, and thyroid cancer have many causes — smoking, diet, genetics, other occupational exposures, random chance. They will point to the fact that these cancers occur in the general population at a baseline rate, and they will argue that your cancer was one of the “background” cases, not caused by AFFF. The counter: specific causation expert testimony, built on your documented exposure history, your serum PFAS levels, the dose-response literature, and the C8 Science Panel’s probable-link findings. The defense cannot prove your cancer came from something else — they can only raise the possibility. Our job is to make the PFAS explanation the most compelling one.
Play 2: “You assumed the risk.” The defense may argue that firefighters knew the job was dangerous, that they knew chemicals were involved, and that they accepted that risk by choosing the profession. The counter: assumption of risk requires knowing acceptance of the specific danger. A firefighter who knew the job involved fire does not thereby assume the risk of cancer from a chemical they were never told about. The manufacturer’s duty to warn runs to the end user — and the end user was never warned. New Jersey law, like most states, does not let a manufacturer escape liability by saying the user should have known the product was dangerous when the manufacturer itself never said so.
Play 3: “You waited too long.” The defense will argue that the statute of limitations has expired — that years or decades passed between the exposure and the lawsuit. The counter: the discovery rule. For toxic tort cases, New Jersey follows the discovery rule — the clock starts when you discovered or reasonably should have discovered both the injury and its cause. If you were diagnosed with kidney cancer in 2020 but did not learn until 2026 that AFFF contained cancer-causing PFAS, the clock may have started in 2026, not 2020. If the manufacturer concealed the danger, fraudulent concealment may toll the limitations period further. This is a fact-specific, case-by-case analysis — and it is why you should never assume you are out of time without consulting a lawyer who understands toxic tort accrual.
Play 4: The slow walk. Mass tort defendants are masters of delay. They file motions to dismiss, motions to transfer, motions to consolidate. They challenge expert qualifications. They seek stays pending MDL developments. Every motion is a month. Every stay is a quarter. The goal is to wear you down — to make the financial pressure of being sick and not working push you toward accepting less than your case is worth. The counter: a firm that has the resources and the will to fight through the delay, that files in the right court, that moves to compel discovery, and that keeps the pressure on the other side rather than absorbing it.
Play 5: The lowball early offer. If the defense thinks your case is strong, they may make an early offer — one that sounds large in absolute terms but is a fraction of what the case is worth at trial. The goal is to buy the case cheap before you have a lawyer who can value it. The counter: never accept an offer before your case has been fully evaluated — before your exposure history is documented, your serum levels are tested, your medical records are complete, and a life-care planner has calculated your future costs. A check that arrives fast is usually a check that is small.
The Medicine: How PFAS Causes Cancer in the Human Body
To understand why these cases matter, you need to understand what PFAS does inside the body — because the mechanism is what makes the connection between exposure and disease more than a coincidence.
PFAS compounds are called “forever chemicals” for a reason. The carbon-fluorine bond — the strongest bond in organic chemistry — does not break down under normal environmental or biological conditions. When you absorb PFAS through your skin, your lungs, or your digestive system, it does not get metabolized and eliminated the way most toxins do. It binds to serum proteins — particularly albumin — and circulates in your blood. It accumulates in the liver, the kidneys, and other tissues. The half-life of PFOS in human serum is estimated at approximately 5.4 years. For PFOA, it is estimated at 2 to 4 years, though this varies by individual. That means if you stopped being exposed to AFFF today, half the PFOS in your blood would still be there five years from now.
The proposed mechanisms by which PFAS causes cancer include:
Endocrine disruption. PFAS compounds interfere with hormonal signaling pathways, including thyroid function and estrogen metabolism. Endocrine disruption can promote the growth of hormone-sensitive cancers, including thyroid cancer and certain kidney cancer subtypes.
Oxidative stress. PFAS accumulation in the liver and kidneys generates reactive oxygen species — free radicals that damage DNA, proteins, and cell membranes. Chronic oxidative stress is a recognized mechanism of carcinogenesis. The organs where PFAS concentrates — the kidneys, the liver — are among the organs where PFAS-associated cancers appear.
Immune modulation. PFAS is known to suppress immune function. A suppressed immune system is less effective at detecting and destroying early cancer cells — the kind of cells your immune system eliminates every day before they can establish a tumor. By impairing immune surveillance, PFAS may allow cancers that would otherwise have been caught and cleared to develop into clinical disease.
Epigenetic changes. PFAS exposure has been associated with changes in gene expression that do not alter the DNA sequence itself but change how genes are read — activating pathways that promote cell proliferation and deactivating pathways that suppress tumor growth.
The latency period — the time between initial exposure and cancer diagnosis — can be years or decades. This is why the discovery rule matters so much in these cases. A firefighter who started using AFFF in 1990 and was diagnosed with kidney cancer in 2023 may have a 33-year latency period. The exposure happened long ago. The disease appeared recently. The connection between the two may not have been understood until even more recently — when the government started calling the foam “cancer-causing.”
The Proof Story: How a PFAS Cancer Case Is Actually Built
Here is how a case like this moves from a cancer diagnosis to a compensated claim. This is the process, told by someone who has lived it.
Week one: the preservation letter goes out. The day you call, letters go to the fire department (for purchase records, training logs, incident reports), to the manufacturers (for internal documents, safety studies, warning decisions), and to any gear manufacturers (for PFAS content testing). These letters create a legal obligation to preserve evidence. If records are destroyed after a preservation letter is on file, the consequences are severe.
The exposure history is documented. We sit down with you — in English or in Spanish — and reconstruct your career. Which departments did you serve with? When did you use AFFF? How often? In what quantities? At training exercises? At emergency calls? At equipment testing? Did you handle concentrate? Did you clean up after foam discharge? Did you store foam at the station? Every detail is documented because the exposure history is what dose reconstruction is built on.
Serum PFAS testing is ordered. You get a blood draw at a specialized laboratory. The results show your current body burden of PFOA, PFOS, PFHxS, and other PFAS compounds. These numbers are the biomarker evidence that links your exposure to your internal dose — the foundation for specific causation.
The medical record is assembled. Every pathology report, every imaging study, every treatment record, every oncology note. The medical record documents the cancer — its type, its stage, its treatment, its prognosis. It also documents the timeline: when was the cancer first detected? When did symptoms begin? When was the diagnosis confirmed?
The expert team is retained. A board-certified oncologist or epidemiologist for specific causation testimony — the expert who will testify, to a reasonable degree of medical certainty, that your cancer was caused by your PFAS exposure. A toxicologist for dose reconstruction — the expert who calculates how much PFAS you absorbed over your career and compares it to the doses associated with elevated cancer risk in the published literature. An industrial hygienist for exposure assessment — the expert who reconstructs the conditions under which you were exposed and the likely dose you received.
Discovery proceeds. In the MDL or in individual state-court litigation, the manufacturers are required to produce internal documents — communications about PFAS toxicity, safety testing results, warning-label decisions, marketing materials, regulatory submissions. These documents are where the manufacturer’s knowledge — or lack of it — is revealed. They drive both liability and punitive damages.
The case is valued. A life-care planner builds the cost of your future medical care — ongoing treatment, surveillance, medication, potential recurrence. A forensic economist calculates your lost earnings and lost earning capacity. The non-economic damages — the pain, the fear, the loss of the life you expected to live — are part of the demand. If the manufacturer’s conduct supports it, punitive damages are part of the demand as well.
The case resolves — through settlement or trial. Most mass tort cases resolve through settlement, typically within a framework established by the MDL’s bellwether results. But the willingness to try a case — to take it in front of a jury — is what gives a settlement demand its teeth. A firm that never tries cases gets low settlements. A firm that tries cases gets real ones.
Your First Steps: What to Do Right Now
If you are a firefighter — active or retired — and you have been diagnosed with kidney cancer, testicular cancer, thyroid cancer, prostate cancer, or another condition associated with PFAS exposure, here is what you should do:
Get your serum PFAS levels tested. This is the single most time-sensitive medical step. Your PFAS body burden is declining slowly but continuously. The test you take today is more accurate than the one you take next year. Talk to your doctor or contact a lawyer who can help arrange testing through a qualified laboratory.
Document your exposure history. Write down everything you can remember about your use of AFFF — which departments, which years, how often, in what contexts. List the training exercises where foam was used. List the emergency calls where foam was deployed. List the equipment testing events. List the foam brands and products you used, if you know them. This information is the raw material for dose reconstruction.
Preserve your turnout gear. If you have turnout gear that was used during the period of AFFF exposure, do not discard it. It may contain PFAS residues that can be tested. That testing can support a parallel claim against gear manufacturers.
Gather your medical records. Get copies of your pathology reports, imaging studies, treatment records, and oncology notes. These document the cancer and its timeline.
Do not sign anything from an insurance company or manufacturer. If someone contacts you offering a settlement or asking you to sign a release, do not sign it. A release is a legal document that extinguishes your right to sue. Once you sign it, your case is over — regardless of what you later learn about the connection between the foam and your cancer.
Call a lawyer. The consultation is free. The call is confidential. We do not get paid unless we win your case. And the preservation letter — the letter that freezes the evidence before it disappears — goes out the day you call. You can reach us at 1-888-ATTY-911.
If you are a family member of a firefighter who died of cancer, and you believe the cancer may be connected to AFFF exposure, the same steps apply. Wrongful death and survival claims may be viable if the connection to AFFF exposure was not understood during the decedent’s lifetime. The discovery rule may mean the clock started running later than you think.
Frequently Asked Questions
I used AFFF for years and now I have kidney cancer. Can I sue the manufacturer?
Yes, you may have a product liability claim against the manufacturer of the AFFF you used. The claim would be based on design defect (the product’s core ingredient is a bioaccumulative carcinogen), failure to warn (you were never told the foam could cause cancer), and potentially fraudulent concealment (if the manufacturer knew of the cancer risk and suppressed it). The strength of your claim depends on your documented exposure history, your serum PFAS levels, your cancer type, and the quality of your specific causation expert testimony. The general causation link between PFAS and kidney cancer is well-established — the C8 Science Panel found a “probable link” between PFOA and kidney cancer, and the IARC has classified PFOA as a Group 1 human carcinogen.
How long do I have to file a lawsuit?
New Jersey’s statute of limitations for personal injury claims is two years, and the same two-year window applies to wrongful death claims. But for toxic tort cases like AFFF/PFAS exposure, New Jersey follows the discovery rule — meaning the clock may not start running until you discovered, or reasonably should have discovered, both your injury (the cancer diagnosis) and its potential cause (the AFFF/PFAS exposure). If you were diagnosed with cancer years ago but only recently learned that AFFF contained cancer-causing PFAS, your deadline may have started running more recently than you think. This is a fact-specific analysis that depends on your individual circumstances — and it is why you should not assume you are out of time without consulting a lawyer who understands toxic tort accrual.
I’m a firefighter but I haven’t been diagnosed with cancer. Should I still do anything?
Yes. You should get your serum PFAS levels tested — this establishes your current body burden and provides baseline data for future comparison. You should document your exposure history while your memory is fresh. And you should explore whether a medical monitoring claim is available to you — a claim that seeks the cost of periodic cancer screening and diagnostic surveillance from the manufacturers who exposed you. Medical monitoring claims carry lower individual values than cancer claims, but they provide something valuable: ongoing surveillance that catches disease early, when it is most treatable. The testing you do now is also the foundation for a stronger case if you are diagnosed later.
Does the New Jersey collection program mean the government is admitting the foam causes cancer?
The state’s own officials called the foam “cancer-causing” in the announcement of the collection program. The DCA commissioner said the program was about “stopping the use of cancer-causing firefighting foam.” The NJFMBA president said “cancer in the fire service is our number one killer.” These are official government statements, made in an official government press release, by named officials. They do not constitute a legal admission of liability by the foam manufacturers — but they are powerful evidence that the danger is recognized, documented, and serious enough to warrant a $16.6 million government response. In a product liability case, the fact that a state government concluded the product is cancer-causing and passed legislation to ban it makes the manufacturer’s “no one knew” defense very difficult to maintain.
What if my loved one was a firefighter who died of cancer — is it too late to file a claim?
Not necessarily. New Jersey’s wrongful death statute provides a two-year limitations period, but the discovery rule may apply — meaning the clock may not have started running until the connection between the cancer and the AFFF exposure was discovered or should have been discovered. If your loved one died of kidney cancer in 2018, and you did not learn until 2026 that AFFF contained cancer-causing PFAS, the discovery rule may mean your deadline started running in 2026. Survival claims — which capture the decedent’s pre-death pain and suffering — may also be viable. This is a fact-specific analysis, and you should not assume the claim is time-barred without consulting a lawyer.
Are the AFFF settlements I’ve heard about in the news — the 3M and DuPont settlements — do those cover firefighters?
No. The settlements you have heard about — 3M’s approximately $10.3 billion agreement and the DuPont/Chemours/Corteva approximately $1.185 billion agreement — are settlements with public water providers. They resolve claims by cities and water utilities for the cost of removing PFAS from public drinking water supplies. They do not cover personal-injury claims by firefighters who developed cancer after exposure to AFFF. Those personal-injury cases are a separate track within the AFFF MDL and in individual state-court filings. A firefighter with cancer is not automatically covered by the water-system money — they need their own claim.
What if I was exposed to AFFF in a state other than New Jersey?
The AFFF MDL in the District of South Carolina is a federal proceeding that includes cases from across the country. While this page focuses on New Jersey because of the state’s groundbreaking collection program, the legal theories and the litigation framework apply nationwide. If you were exposed to AFFF in another state, your case may still be part of the MDL or may be filed in your state’s courts, depending on the circumstances. The statute of limitations and the legal framework vary by state — contact us and we can help you understand what applies to your situation.
How much does it cost to hire a lawyer for an AFFF cancer case?
Nothing upfront. We work on contingency — we do not get paid unless we win your case. The fee is 33.33% of the recovery before trial and 40% if the case goes to trial. The consultation is free. The call is confidential. And we have 24/7 live staff — not an answering service — so when you call 1-888-ATTY-911, you reach a person, not a recording.
Can I still file a claim if I smoked or had other risk factors for cancer?
Yes. New Jersey follows a modified comparative negligence rule — your own share of fault reduces your recovery, but it does not bar it unless you are found to be 50% or more at fault. More importantly, the eggshell-plaintiff doctrine — recognized across U.S. jurisdictions — means that a defendant takes the victim as found. If you had risk factors that made you more susceptible to cancer, the manufacturer does not get to use that as a shield. The question is not whether you were perfectly healthy — it is whether the AFFF exposure caused or contributed to your cancer. Smoking, diet, and other factors are alternative-cause arguments the defense will raise, but they do not eliminate the manufacturer’s liability if the PFAS exposure was a contributing cause.
What if I don’t know which brand of AFFF I used?
Most firefighters do not know the specific brand of AFFF they used — and that is not a barrier to filing a claim. Fire departments purchased AFFF from various suppliers over the years, and the purchase records are in the department’s files. Part of what we do is obtain those records through preservation demands and discovery. The MDL framework also allows for claims against multiple manufacturers — you do not need to prove which specific brand caused your specific cancer. You need to prove that you were exposed to PFAS-containing AFFF and that the exposure caused or contributed to your disease.
Is the gear I wore also a source of PFAS exposure?
Yes. The NJFMBA president specifically identified contaminated turnout gear as a separate exposure pathway. PFAS has been used in the manufacture of turnout gear, and firefighters can absorb it through dermal contact — especially when the gear is hot and the skin is sweating, which increases dermal absorption. Gear manufacturers face their own potential product-liability and failure-to-warn exposure for PFAS in protective equipment. If you have turnout gear from your period of AFFF exposure, it should be preserved and tested — it may support a parallel claim against the gear manufacturer.
Why Attorney911
We are not a firm that files AFFF cases as a side practice. Toxic exposure litigation is central to what we do. Ralph Manginello has 27-plus years of trial practice — in state and federal court — and before he was a lawyer, he was a journalist. He learned to find the documents that people do not want found, and he learned to tell the story that those documents reveal. That skill set — investigative, narrative, relentless — is exactly what a mass tort toxic exposure case demands.
Lupe Peña is a former insurance-defense attorney. He spent years inside a national defense firm, in the rooms where adjusters and their software — systems like Colossus — decided how to value, deny, and devalue claims from injured people. He knows how the reserve is set in the first 48 hours. He knows how the recorded-statement call is engineered. He knows how the IME doctor is selected. He knows the delay tactics, the surveillance, the social-media monitoring. And now he uses that knowledge for injured clients — because the best way to beat the playbook is to have someone on your side who wrote it. Lupe is fluent in Spanish and conducts full client consultations in Spanish without an interpreter.
We handle these cases on contingency. You pay nothing upfront. We do not get paid unless we win your case. The fee is 33.33% before trial, 40% if the case goes to trial. The consultation is free. The call is confidential. And we have 24/7 live staff — not an answering service — so when you call, you reach a person.
We work with local counsel in states where we are not licensed, filing pro hac vice where required, because the right to hold a corporation accountable for poisoning you should not depend on where the corporation happened to be headquartered. You can read more about Ralph and Lupe on our attorneys page, or learn more about our firm on our homepage.
If you are a firefighter — or the family of a firefighter — who has been diagnosed with a cancer associated with PFAS exposure, the most important thing you can do today is this: call. The preservation letter goes out the day you call. The evidence that proves your case is on a clock, and that clock is running. The consultation is free. The call is confidential. We do not get paid unless we win.
Call 1-888-ATTY-911. Hablamos Español.
This page is legal information, not legal advice. Every case depends on its own facts. Past results depend on the facts of each case and do not guarantee future outcomes. Contacting the firm is free and confidential.